Prostaglandin D2 induces apoptosis of human osteoclasts by activating the CRTH2 receptor and the intrinsic apoptosis pathway.
Prostaglandin D(2) (PGD(2)) is a lipid mediator synthesized from arachidonic acid that directly activates two specific receptors, the D-type prostanoid (DP) receptor and chemoattractant receptor homologous molecule expressed on T-helper type 2 cells (CRTH2). PGD(2) can affect bone metabolism by influencing both osteoblast and osteoclast (OC) functions, both cells involved in bone remodeling and in in vivo fracture repair as well. The objective of the present study was to determine the effects of PGD(2), acting through its two specific receptors, on human OC apoptosis. Human OCs were differentiated in vitro from peripheral blood mononuclear cells in the presence of receptor activator for nuclear factor κB ligand (RANKL) and macrophage-colony stimulating factor (M-CSF), and treated with PGD(2), its specific agonists and antagonists. Treatment with PGD(2) for 24hours in the presence of naproxen (10μM) to inhibit endogenous prostaglandin production increased the percentage of apoptotic OCs in a dose-dependent manner, as did the specific CRTH2 agonist compound DK-PGD(2) but not the DP agonist compound BW 245C. In the absence of naproxen, the CRTH2 antagonist compound CAY 10471 reduced OC apoptosis rate but the DP antagonist BW A868C had no effect. The induction of PGD(2)-CRTH2 dependent apoptosis was associated with the activation of caspase-9, but not caspase-8, leading to caspase-3 cleavage. These data show that PGD(2) induces human OC apoptosis through activation of CRTH2 and the apoptosis intrinsic pathway.
Division of Rheumatology, Department of Medicine, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, Quebec, Canada. Li.Yue@USherbrooke.ca
Li
L
Yue
Marianne
M
Durand
M Christian
MC
Lebeau Jacob
Philippe
P
Hogan
Stephen
S
McManus
Sophie
S
Roux
Artur J
AJ
de Brum-Fernandes
D000135:Acid Phosphatase / Q000378:metabolism; D017209:Apoptosis / Q000187:drug effects*; D015153:Blotting, Western; D020169:Caspases / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism; D010010:Osteoclasts / Q000166:cytology* / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D015230:Prostaglandin D2 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D011971:Receptors, Immunologic / Q000378:metabolism*; D011982:Receptors, Prostaglandin / Q000378:metabolism*; D044967:Serum; D015398:Signal Transduction / Q000187:drug effects*; D013194:Staining and Labeling; D000071681:Tartrate-Resistant Acid Phosphatase
D007527:Isoenzymes; D011971:Receptors, Immunologic; D011982:Receptors, Prostaglandin; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase; D020169:Caspases; D015230:Prostaglandin D2; C036293:prostaglandin D2 receptor